Tatva Chintan Pharma Chem Ltd. Presents Investor Presentation for Q4FY26 & FY26
Tatva Chintan Pharma Chem Ltd. reported a 32% YoY increase in FY26 revenue to ₹5,059 million and a 636% surge in PAT to ₹421 million. Q4FY26 revenue grew 24% YoY to ₹1,341 million, with PAT rising 902% to ₹103 million. The company's EBITDA margin improved significantly in both FY26 and Q4FY26.
The substantial increase in financial metrics such as revenue, EBITDA, and PAT, along with improved margins, is a material development for the company's stakeholders.
The company has reported significant year-on-year growth in revenue, EBITDA, and PAT for both the financial year and the fourth quarter, indicating strong financial performance.
Tatva Chintan Pharma Chem Limited (TCPCL) has released its Investor Presentation for the quarter and financial year ended March 31, 2026. The presentation details the company's financial performance, operational highlights, and strategic initiatives.
For the financial year 2026 (FY26), TCPCL reported a Revenue from Operations of ₹5,059 million, a significant 32% increase compared to ₹3,827 million in FY25. EBITDA (excluding other income) also saw a substantial rise of 172% to ₹932 million from ₹342 million in the previous year, with the EBITDA margin improving to 18.4% from 8.9% in FY25.
The company's Profit After Tax (PAT) for FY26 surged by 636% to ₹421 million from ₹57 million in FY25, with the PAT margin increasing to 8.3% from 1.5%. Earnings Per Share (EPS) for FY26 stood at ₹17.98, a considerable jump from ₹2.44 in FY25.
In the fourth quarter of FY26 (Q4FY26), Revenue from Operations was ₹1,341 million, a 24% increase year-on-year from ₹1,079 million in Q4FY25. EBITDA (excluding other income) for Q4FY26 rose by 214% to ₹281 million from ₹90 million in Q4FY25, with the EBITDA margin improving to 21.0% from 8.3%. PAT for Q4FY26 was ₹103 million, a 902% increase from ₹10 million in Q4FY25, and the PAT margin stood at 7.7%. EPS for Q4FY26 was ₹4.41.
The presentation also highlights the company's product portfolio, including Phase Transfer Catalysts (PTC), Structure Directing Agents (SDA), Electrolyte Salts (ESS), and Pharma & Agrochemical Intermediates (PASC). TCPCL emphasizes its commitment to green chemistry processes, including electrolysis and continuous flow chemistry, and its expansive international presence with a customer base spanning over 25 countries.
What to do with a filing like this
Tatva Chintan Pharma Chem Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Tatva Chintan Pharma Chem Limited. Read the original for the full detail.